315 related articles for article (PubMed ID: 28645211)
1. AKR1C3-Mediated Adipose Androgen Generation Drives Lipotoxicity in Women With Polycystic Ovary Syndrome.
O'Reilly MW; Kempegowda P; Walsh M; Taylor AE; Manolopoulos KN; Allwood JW; Semple RK; Hebenstreit D; Dunn WB; Tomlinson JW; Arlt W
J Clin Endocrinol Metab; 2017 Sep; 102(9):3327-3339. PubMed ID: 28645211
[TBL] [Abstract][Full Text] [Related]
2. Insulin-Induced AKR1C3 Induces Fatty Acid Synthase in a Model of Human PCOS Adipocytes.
Paulukinas RD; Penning TM
Endocrinology; 2023 Mar; 164(5):. PubMed ID: 36799021
[TBL] [Abstract][Full Text] [Related]
3. Serum metabolomics profiling by proton nuclear magnetic resonance spectrometry of the response to single oral macronutrient challenges in women with polycystic ovary syndrome (PCOS) compared with male and female controls.
Escobar-Morreale HF; Martínez-García MÁ; Insenser M; Cañellas N; Correig X; Luque-Ramírez M
Biol Sex Differ; 2023 Sep; 14(1):62. PubMed ID: 37736753
[TBL] [Abstract][Full Text] [Related]
4. Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study.
Gashaw I; Reif S; Wiesinger H; Kaiser A; Zollmann FS; Scheerans C; Grevel J; Piraino P; Seidel H; Peters M; Rottmann A; Rohde B; Arlt W; Hilpert J
Eur J Endocrinol; 2023 Jul; 188(7):578-591. PubMed ID: 37306288
[TBL] [Abstract][Full Text] [Related]
5. AKR1C3 as a target in castrate resistant prostate cancer.
Adeniji AO; Chen M; Penning TM
J Steroid Biochem Mol Biol; 2013 Sep; 137():136-49. PubMed ID: 23748150
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
Himura R; Kawano S; Nagata Y; Kawai M; Ota A; Kudo Y; Yoshino Y; Fujimoto N; Miyamoto H; Endo S; Ikari A
Chem Biol Interact; 2024 Jan; 388():110840. PubMed ID: 38122923
[TBL] [Abstract][Full Text] [Related]
7. Impaired Lipolysis, Diminished Fat Oxidation, and Metabolic Inflexibility in Obese Girls With Polycystic Ovary Syndrome.
Kim JY; Tfayli H; Michaliszyn SF; Arslanian S
J Clin Endocrinol Metab; 2018 Feb; 103(2):546-554. PubMed ID: 29220530
[TBL] [Abstract][Full Text] [Related]
8. Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction.
González F
Steroids; 2012 Mar; 77(4):300-5. PubMed ID: 22178787
[TBL] [Abstract][Full Text] [Related]
9. Adipose Tissue Dysfunction in Polycystic Ovary Syndrome.
Bril F; Ezeh U; Amiri M; Hatoum S; Pace L; Chen YH; Bertrand F; Gower B; Azziz R
J Clin Endocrinol Metab; 2023 Dec; 109(1):10-24. PubMed ID: 37329216
[TBL] [Abstract][Full Text] [Related]
10. Myricetin ameliorates polycystic ovary syndrome in mice by brown adipose tissue activation.
Zheng N; Wang C; Li Y; Fu H; Hu T
Reproduction; 2024 Jun; 167(6):. PubMed ID: 38520750
[TBL] [Abstract][Full Text] [Related]
11. Androgen excess: a hallmark of polycystic ovary syndrome.
Wang K; Li Y; Chen Y
Front Endocrinol (Lausanne); 2023; 14():1273542. PubMed ID: 38152131
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the glucocorticoid-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 drives concurrent 11-oxygenated androgen excess.
Schiffer L; Oestlund I; Snoep JL; Gilligan LC; Taylor AE; Sinclair AJ; Singhal R; Freeman A; Ajjan R; Tiganescu A; Arlt W; Storbeck KH
FASEB J; 2024 Apr; 38(7):e23574. PubMed ID: 38551804
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis shows decreased type I fibers and ectopic fat accumulation in skeletal muscle from women with PCOS.
Stener-Victorin E; Eriksson G; Mohan Shrestha M; Rodriguez Paris V; Lu H; Banks J; Samad M; Perian C; Jude B; Engman V; Boi R; Nilsson E; Ling C; Nyström J; Wernstedt Asterholm I; Turner N; Lanner J; Benrick A
Elife; 2024 Jan; 12():. PubMed ID: 38180081
[TBL] [Abstract][Full Text] [Related]
14. Dingkun pill alleviates metabolic abnormalities in polycystic ovary syndrome through brown adipose tissue activation.
Gu M; Cai H; Deng W; Tang Y; Du S; Wang P; Deng W; Wang H; Sun A; Kong S
J Ovarian Res; 2023 Aug; 16(1):176. PubMed ID: 37633943
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor actions on AgRP neurons are not a major cause of reproductive and metabolic impairments in peripubertally androgenized mice.
Kerbus RI; Decourt C; Inglis MA; Campbell RE; Anderson GM
J Neuroendocrinol; 2024 Mar; 36(3):e13370. PubMed ID: 38344844
[TBL] [Abstract][Full Text] [Related]
16. An Evolutionary Model for the Ancient Origins of Polycystic Ovary Syndrome.
Dumesic DA; Abbott DH; Chazenbalk GD
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834765
[TBL] [Abstract][Full Text] [Related]
17. Artemisinins ameliorate polycystic ovarian syndrome by mediating LONP1-CYP11A1 interaction.
Liu Y; Jiang JJ; Du SY; Mu LS; Fan JJ; Hu JC; Ye Y; Ding M; Zhou WY; Yu QH; Xia YF; Xu HY; Shi YJ; Qian SW; Tang Y; Li W; Dang YJ; Dong X; Li XY; Xu CJ; Tang QQ
Science; 2024 Jun; 384(6701):eadk5382. PubMed ID: 38870290
[TBL] [Abstract][Full Text] [Related]
18. Genetic factors modulate the impact of pubertal androgen excess on insulin sensitivity and fertility.
Dowling AR; Nedorezov LB; Qiu X; Marino JS; Hill JW
PLoS One; 2013; 8(11):e79849. PubMed ID: 24278193
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid Receptor Antagonism Improves Glucose Metabolism in a Mouse Model of Polycystic Ovary Syndrome.
Li S; Ying Z; Gentenaar M; Rensen PCN; Kooijman S; Visser JA; Meijer OC; Kroon J
J Endocr Soc; 2023 Dec; 8(1):bvad162. PubMed ID: 38169733
[TBL] [Abstract][Full Text] [Related]
20. Intrauterine androgen exposure impairs gonadal adipose tissue functions of adult female rats.
Ferrer MJ; Abruzzese GA; Heber MF; Ferreira SR; Campo Verde Arbocco F; Motta AB
Theriogenology; 2023 Mar; 198():131-140. PubMed ID: 36584634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
